HR-2004-119
Forwarded by Subcommittee to Full Committee by Voice Vote.
Sponsored by Ted Lieu (D-CA)
What it does
This bill would direct the Secretary of Health and Human Services (HHS) to complete a study within one year examining how often hospital emergency departments test overdose patients specifically for fentanyl, the costs of such testing, the potential benefits and risks to patients, and effects on patient privacy and the patient-physician relationship. Within six months after completing that study, HHS would be required to issue non-binding guidance on whether emergency departments should make fentanyl testing a routine procedure for overdose patients, how hospitals can ensure clinicians know which substances are included in standard drug tests, and how fentanyl testing may affect future overdose risk and general health outcomes.
Who benefits
Overdose patients who may receive more accurate diagnoses and targeted treatment if fentanyl testing becomes routine. Emergency physicians and nurses who would gain clearer guidance on standard-of-care testing protocols. Hospital administrators seeking a federal benchmark for testing practices. Public health researchers and policymakers who would gain nationally collected data on current fentanyl testing rates. Families of overdose patients who may benefit from improved clinical outcomes. Fentanyl test strip and toxicology equipment manufacturers who could see increased demand if guidance recommends routine testing.
Who is hurt
Hospitals and health systems that may face implementation costs if guidance leads to broader adoption of fentanyl-specific testing. Patients concerned about privacy, as expanded toxicology testing could generate additional sensitive health records. Patients in jurisdictions with mandatory reporting laws who may face legal exposure if fentanyl is detected and reported. Insurers and payers who could bear increased testing costs if routine fentanyl screening becomes a standard billing item. The bill imposes a one-year study and six-month guidance deadline on HHS, adding to the agency's administrative workload.
Supporters argue
Supporters argue that fentanyl is now involved in the majority of U.S. overdose deaths — over 73,000 in 2022 according to CDC data — yet standard emergency department drug panels often do not detect synthetic opioids like fentanyl, meaning clinicians may be treating overdoses without knowing the actual substance involved. They contend that evidence-based federal guidance would help standardize care across hospitals, potentially improving treatment decisions such as naloxone dosing and follow-up referrals, and that the study-first approach ensures any recommendations are grounded in real-world cost and outcome data rather than assumption.
Opponents argue
Opponents argue that the bill adds a layer of federal bureaucracy — a mandated study plus a guidance document — for a clinical question that hospitals and medical professional societies are already equipped to address without federal direction. They contend that non-binding guidance from HHS may create de facto liability pressure on hospitals to adopt testing regardless of local patient populations or resource constraints, and that expanding toxicology testing raises genuine patient privacy concerns, particularly in states where positive drug tests can trigger legal consequences, potentially deterring at-risk individuals from seeking emergency care in the future.